مورد إلكتروني
Plasma levels of hemostasis inhibitors and MRI outcomes in multiple sclerosis (P3.368)
العنوان: | Plasma levels of hemostasis inhibitors and MRI outcomes in multiple sclerosis (P3.368) |
---|---|
بيانات النشر: | Lippincott, Williams & Wilkins 2018 |
تفاصيل مُضافة: | Ziliotto, N Bernardi, F Jakimovski, D Baroni, M Marchetti, G Bergsland, N Weinstock-Guttman, B Zamboni, P Ramanathan, M Zivadinov, R Ziliotto Nicole Bernardi Francesco Jakimovski Dejan Baroni Marcello Marchetti Giovanna Bergsland Niels Weinstock-Guttman Bianca Zamboni Paolo Ramanathan Murali Zivadinov Robert |
نوع الوثيقة: | Electronic Resource |
مستخلص: | Objective: To investigate the association between plasma levels of hemostasis inhibitors and MRI outcomes in multiple sclerosis (MS).Background: The role of hemostasis inhibitors in MS is not well understood. Several studies suggest the crosstalk between inflammation, immunity and coagulation in the MS pathogenesis. Improved knowledge of the role of hemostasis inhibitors could lead to better understanding of the anticoagulation/anti-inflammatory pathways in MS.Design/Methods: 3T MRI exams and plasma levels of hemostasis inhibitors levels were evaluated in 138 MS patients (mean age, 54 years; 72.5% female; median EDSS 3.5; average mean disease duration 21 years) and 42 age- and sex-matched healthy individuals (HI), collected in the Cardiovascular, Genetic and Environmental (CEG) study in MS. In particular, disintegrin-like and metalloprotease with thrombospondin type 1 motif 13 (ADAMTS13), heparin cofactor II (HCII), tissue factor pathway inhibitor (TFPI) and thrombomodulin (TM) plasma profiles were evaluated by magnetic Luminex assays and ELISA. Associations between hemostasis inhibitors and MRI outcomes were assessed. Results: Lower ADAMTS13 levels were found in MS patients compared to HI (1548±481 ng/mL vs 1733±562 ng/mL, p=0.038), and in MS with cerebral microbleeds compared to those without (1257±459 ng/mL vs 1566±479 ng/mL, p=0.028). In HI, decreased HCII levels were associated with larger cortical (p=0.003), brain parenchyma (p=0.005) and thalamus (p=0.013) volumes, and lower lateral ventricular volume (p=0.043) and T2 (p=0.045) lesion volumes (p=0.048).Conclusions: Normal levels of HCII, TM and TFPI, and decreased ADAMTS13 levels, particularly in patients with cerebral microbleeds are observed in MS patients. Data suggest a protective role of HCII on MRI outcomes in HI, not evident in MS patients. Further studies are needed to clarify the association of hemostasis inhibitors with the tissue injury in the CNS. |
مصطلحات الفهرس: | hemostasis inhibitor, MRI, multiple sclerosi, ADAMTS13, heparin cofactor II, TFPI, thrombomodulin, neurodegeneration, cerebral microbleeds, info:eu-repo/semantics/conferenceObject |
URL: | ispartofbook:70th Annual American Academy of Neurology (AAN) Meeting 70th Annual American Academy of Neurology (AAN) Meeting 24 april volume:90 issue:15 Supplement firstpage:P3.368 lastpage:P3.368 numberofpages:1 journal:NEUROLOGY |
الإتاحة: | Open access content. Open access content |
ملاحظة: | ELETTRONICO English |
أرقام أخرى: | ITBAO oai:boa.unimib.it:10281/275997 1311397325 |
المصدر المساهم: | BICOCCA OPEN ARCH From OAIster®, provided by the OCLC Cooperative. |
رقم الأكسشن: | edsoai.on1311397325 |
قاعدة البيانات: | OAIster |
الوصف غير متاح. |